E
XORTX Therapeutics Inc.
XRTX
$0.87
-$0.1026-10.55%
E
Sell
12/11/2023Downgrade
XORTX Therapeutics Inc. (XRTX) was downgraded to E+ from D- on 12/11/2023 due to a decline in the volatility index and total return index.
XORTX Therapeutics Inc. (XRTX) was downgraded to E+ from D- on 12/11/2023 due to a decline in the volatility index and total return index.
D
Sell
11/24/2023Upgraded
XORTX Therapeutics Inc. (XRTX) was upgraded to D- from E+ on 11/24/2023 due to an increase in the volatility index.
XORTX Therapeutics Inc. (XRTX) was upgraded to D- from E+ on 11/24/2023 due to an increase in the volatility index.
E
Sell
11/17/2023Downgrade
XORTX Therapeutics Inc. (XRTX) was downgraded to E+ from D- on 11/17/2023 due to a decline in the volatility index and total return index.
XORTX Therapeutics Inc. (XRTX) was downgraded to E+ from D- on 11/17/2023 due to a decline in the volatility index and total return index.
D
Sell
11/1/2023Upgraded
XORTX Therapeutics Inc. (XRTX) was upgraded to D- from E+ on 11/1/2023 due to an increase in the volatility index.
XORTX Therapeutics Inc. (XRTX) was upgraded to D- from E+ on 11/1/2023 due to an increase in the volatility index.
E
Sell
10/13/2023Downgrade
XORTX Therapeutics Inc. (XRTX) was downgraded to E+ from D- on 10/13/2023 due to a decline in the volatility index.
XORTX Therapeutics Inc. (XRTX) was downgraded to E+ from D- on 10/13/2023 due to a decline in the volatility index.
D
Sell
8/22/2023Upgraded
XORTX Therapeutics Inc. (XRTX) was upgraded to D- from E+ on 8/22/2023 due to an increase in the growth index and volatility index. Operating cash flow increased 30.32% from -$2.48M to -$1.73M, EBIT increased 11.23% from -$1.68M to -$1.49M, and earnings per share increased from -$0.1055 to -$0.094.
XORTX Therapeutics Inc. (XRTX) was upgraded to D- from E+ on 8/22/2023 due to an increase in the growth index and volatility index. Operating cash flow increased 30.32% from -$2.48M to -$1.73M, EBIT increased 11.23% from -$1.68M to -$1.49M, and earnings per share increased from -$0.1055 to -$0.094.
E
Sell
8/3/2023Downgrade
XORTX Therapeutics Inc. (XRTX) was downgraded to E+ from D- on 8/3/2023 due to a decline in the volatility index and growth index.
XORTX Therapeutics Inc. (XRTX) was downgraded to E+ from D- on 8/3/2023 due to a decline in the volatility index and growth index.
D
Sell
7/18/2023Upgraded
XORTX Therapeutics Inc. (XRTX) was upgraded to D- from E+ on 7/18/2023 due to a noticeable increase in the growth index, volatility index and solvency index. The quick ratio increased from 6.94 to 13.25, operating cash flow increased 34.62% from -$3.8M to -$2.48M, and EBIT increased 31.42% from -$2.45M to -$1.68M.
XORTX Therapeutics Inc. (XRTX) was upgraded to D- from E+ on 7/18/2023 due to a noticeable increase in the growth index, volatility index and solvency index. The quick ratio increased from 6.94 to 13.25, operating cash flow increased 34.62% from -$3.8M to -$2.48M, and EBIT increased 31.42% from -$2.45M to -$1.68M.
E
Sell
4/10/2023Downgrade
XORTX Therapeutics Inc. (XRTX) was downgraded to E+ from D on 4/10/2023 due to a significant decline in the valuation index, efficiency index and growth index. Operating cash flow declined 299.4% from -$951.2 to -$3.8M, net income declined 79.53% from -$1.2M to -$2.15M, and earnings per share declined from -$0.0922 to -$0.1503.
XORTX Therapeutics Inc. (XRTX) was downgraded to E+ from D on 4/10/2023 due to a significant decline in the valuation index, efficiency index and growth index. Operating cash flow declined 299.4% from -$951.2 to -$3.8M, net income declined 79.53% from -$1.2M to -$2.15M, and earnings per share declined from -$0.0922 to -$0.1503.
D
Sell
3/24/2023Downgrade
XORTX Therapeutics Inc. (XRTX) was downgraded to D from D+ on 3/24/2023 due to a decline in the volatility index and total return index.
XORTX Therapeutics Inc. (XRTX) was downgraded to D from D+ on 3/24/2023 due to a decline in the volatility index and total return index.
D
Sell
3/8/2023Upgraded
XORTX Therapeutics Inc. (XRTX) was upgraded to D+ from D on 3/8/2023 due to an increase in the volatility index and valuation index.
XORTX Therapeutics Inc. (XRTX) was upgraded to D+ from D on 3/8/2023 due to an increase in the volatility index and valuation index.
D
Sell
2/16/2023Downgrade
XORTX Therapeutics Inc. (XRTX) was downgraded to D from D+ on 2/16/2023 due to a decline in the volatility index.
XORTX Therapeutics Inc. (XRTX) was downgraded to D from D+ on 2/16/2023 due to a decline in the volatility index.
D
Sell
1/31/2023Upgraded
XORTX Therapeutics Inc. (XRTX) was upgraded to D+ from D on 1/31/2023 due to an increase in the volatility index and valuation index.
XORTX Therapeutics Inc. (XRTX) was upgraded to D+ from D on 1/31/2023 due to an increase in the volatility index and valuation index.
D
Sell
1/11/2023Downgrade
XORTX Therapeutics Inc. (XRTX) was downgraded to D from D+ on 1/11/2023 due to a decline in the total return index, volatility index and efficiency index.
XORTX Therapeutics Inc. (XRTX) was downgraded to D from D+ on 1/11/2023 due to a decline in the total return index, volatility index and efficiency index.
D
Sell
12/6/2022Downgrade
XORTX Therapeutics Inc. (XRTX) was downgraded to D+ from C- on 12/6/2022 due to a decline in the volatility index, total return index and valuation index.
XORTX Therapeutics Inc. (XRTX) was downgraded to D+ from C- on 12/6/2022 due to a decline in the volatility index, total return index and valuation index.
C
Hold
11/17/2022Upgraded
XORTX Therapeutics Inc. (XRTX) was upgraded to C- from D on 11/17/2022 due to a significant increase in the valuation index, efficiency index and growth index. Operating cash flow increased 49.47% from -$1.88M to -$950.6, EBIT increased 10.45% from -$2.21M to -$1.98M, and earnings per share increased from -$0.0954 to -$0.0921.
XORTX Therapeutics Inc. (XRTX) was upgraded to C- from D on 11/17/2022 due to a significant increase in the valuation index, efficiency index and growth index. Operating cash flow increased 49.47% from -$1.88M to -$950.6, EBIT increased 10.45% from -$2.21M to -$1.98M, and earnings per share increased from -$0.0954 to -$0.0921.
D
Sell
11/11/2022Upgraded
XORTX Therapeutics Inc. (XRTX) was upgraded to D from D- on 11/11/2022 due to an increase in the growth index, solvency index and valuation index. Earnings per share increased from -$0.2081 to -$0.0954, operating cash flow increased 24.83% from -$2.5M to -$1.88M, and EBIT increased 15.42% from -$2.61M to -$2.21M.
XORTX Therapeutics Inc. (XRTX) was upgraded to D from D- on 11/11/2022 due to an increase in the growth index, solvency index and valuation index. Earnings per share increased from -$0.2081 to -$0.0954, operating cash flow increased 24.83% from -$2.5M to -$1.88M, and EBIT increased 15.42% from -$2.61M to -$2.21M.
D
Sell
8/30/2022Downgrade
XORTX Therapeutics Inc. (XRTX) was downgraded to D- from D on 8/30/2022 due to a decline in the total return index.
XORTX Therapeutics Inc. (XRTX) was downgraded to D- from D on 8/30/2022 due to a decline in the total return index.
D
Sell
8/15/2022Upgraded
XORTX Therapeutics Inc. (XRTX) was upgraded to D from D- on 8/15/2022 due to an increase in the volatility index.
XORTX Therapeutics Inc. (XRTX) was upgraded to D from D- on 8/15/2022 due to an increase in the volatility index.
D
Sell
5/25/2022Downgrade
XORTX Therapeutics Inc. (XRTX) was downgraded to D- from D on 5/25/2022 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 26.97 to 18.3.
XORTX Therapeutics Inc. (XRTX) was downgraded to D- from D on 5/25/2022 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 26.97 to 18.3.
D
Sell
5/5/2022Upgraded
XORTX Therapeutics Inc. (XRTX) was upgraded to D from D- on 5/5/2022 due to an increase in the total return index and valuation index.
XORTX Therapeutics Inc. (XRTX) was upgraded to D from D- on 5/5/2022 due to an increase in the total return index and valuation index.
D
Sell
4/20/2022Downgrade
XORTX Therapeutics Inc. (XRTX) was downgraded to D- from D on 4/20/2022 due to a noticeable decline in the total return index, growth index and volatility index. Operating cash flow declined 5,018.76% from -$61.3 to -$3.14M, and EBIT declined 432.22% from -$197.7 to -$1.05M.
XORTX Therapeutics Inc. (XRTX) was downgraded to D- from D on 4/20/2022 due to a noticeable decline in the total return index, growth index and volatility index. Operating cash flow declined 5,018.76% from -$61.3 to -$3.14M, and EBIT declined 432.22% from -$197.7 to -$1.05M.
D
Sell
12/20/2021Downgrade
XORTX Therapeutics Inc. (XRTX) was downgraded to D from D+ on 12/20/2021 due to a large decline in the total return index and volatility index.
XORTX Therapeutics Inc. (XRTX) was downgraded to D from D+ on 12/20/2021 due to a large decline in the total return index and volatility index.
D
Sell
12/2/2021Upgraded
XORTX Therapeutics Inc. (XRTX) was upgraded to D+ from D on 12/2/2021 due to a large increase in the total return index and valuation index.
XORTX Therapeutics Inc. (XRTX) was upgraded to D+ from D on 12/2/2021 due to a large increase in the total return index and valuation index.
D
Sell
11/23/2021Upgraded
XORTX Therapeutics Inc. (XRTX) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index.
XORTX Therapeutics Inc. (XRTX) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index.
D
Sell
11/8/2021Downgrade
XORTX Therapeutics Inc. (XRTX) was downgraded to D- from D on 11/08/2021.
XORTX Therapeutics Inc. (XRTX) was downgraded to D- from D on 11/08/2021.
D
Sell
2/2/2021Upgraded
XORTX Therapeutics Inc. (XRTXF) was upgraded to D from D- on 2/2/2021 due to a large increase in the total return index and volatility index.
XORTX Therapeutics Inc. (XRTXF) was upgraded to D from D- on 2/2/2021 due to a large increase in the total return index and volatility index.
D
Sell
12/23/2020Upgraded
XORTX Therapeutics Inc. (XRTXF) was upgraded to D- from E+ on 12/23/2020 due to an increase in the total return index and volatility index.
XORTX Therapeutics Inc. (XRTXF) was upgraded to D- from E+ on 12/23/2020 due to an increase in the total return index and volatility index.
E
Sell
12/8/2020Downgrade
XORTX Therapeutics Inc. (XRTXF) was downgraded to E+ from D- on 12/8/2020 due to a large decline in the total return index and volatility index.
XORTX Therapeutics Inc. (XRTXF) was downgraded to E+ from D- on 12/8/2020 due to a large decline in the total return index and volatility index.
D
Sell
10/26/2020Downgrade
XORTX Therapeutics Inc. (XRTXF) was downgraded to D- from D on 10/26/2020 due to a decline in the volatility index.
XORTX Therapeutics Inc. (XRTXF) was downgraded to D- from D on 10/26/2020 due to a decline in the volatility index.
D
Sell
9/17/2020Upgraded
XORTX Therapeutics Inc. (XRTXF) was upgraded to D from D- on 9/17/2020 due to an increase in the total return index and volatility index.
XORTX Therapeutics Inc. (XRTXF) was upgraded to D from D- on 9/17/2020 due to an increase in the total return index and volatility index.
D
Sell
9/2/2020Downgrade
XORTX Therapeutics Inc. (XRTXF) was downgraded to D- from D on 9/2/2020 due to a decline in the valuation index and growth index. Earnings per share declined from -$0.0004 to -$0.0072, and EBIT declined 161.67% from -$87.4 to -$228.7.
XORTX Therapeutics Inc. (XRTXF) was downgraded to D- from D on 9/2/2020 due to a decline in the valuation index and growth index. Earnings per share declined from -$0.0004 to -$0.0072, and EBIT declined 161.67% from -$87.4 to -$228.7.
D
Sell
5/18/2020Upgraded
XORTX Therapeutics Inc. (XRTXF) was upgraded to D from D- on 5/18/2020 due to an increase in the volatility index, total return index and growth index.
XORTX Therapeutics Inc. (XRTXF) was upgraded to D from D- on 5/18/2020 due to an increase in the volatility index, total return index and growth index.
D
Sell
4/30/2020Downgrade
XORTX Therapeutics Inc. (XRTXF) was downgraded to D- from D on 4/30/2020 due to a major decline in the solvency index and growth index. Operating cash flow declined 919.59% from $9.7 to -$79.5, debt to equity increased from -0.49 to -0.24, and the quick ratio declined from 0.11 to 0.06.
XORTX Therapeutics Inc. (XRTXF) was downgraded to D- from D on 4/30/2020 due to a major decline in the solvency index and growth index. Operating cash flow declined 919.59% from $9.7 to -$79.5, debt to equity increased from -0.49 to -0.24, and the quick ratio declined from 0.11 to 0.06.
D
Sell
12/2/2019Upgraded
XORTX Therapeutics Inc. (XRTXF) was upgraded to D from D- on 12/2/2019 due to an increase in the valuation index, efficiency index and volatility index. Net income increased 14.03% from -$116.2 to -$99.9.
XORTX Therapeutics Inc. (XRTXF) was upgraded to D from D- on 12/2/2019 due to an increase in the valuation index, efficiency index and volatility index. Net income increased 14.03% from -$116.2 to -$99.9.
D
Sell
8/1/2019Upgraded
XORTX Therapeutics Inc. (XRTXF) was upgraded to D- from E on 8/1/2019 due to an increase in the valuation index.
XORTX Therapeutics Inc. (XRTXF) was upgraded to D- from E on 8/1/2019 due to an increase in the valuation index.
E
Sell
7/15/2019Downgrade
XORTX Therapeutics Inc. (XRTXF) was downgraded to E from E+ on 7/15/2019 due to a decline in the volatility index, solvency index and total return index. Debt to equity increased from 0.14 to 0.28, and the quick ratio declined from 0.32 to 0.19.
XORTX Therapeutics Inc. (XRTXF) was downgraded to E from E+ on 7/15/2019 due to a decline in the volatility index, solvency index and total return index. Debt to equity increased from 0.14 to 0.28, and the quick ratio declined from 0.32 to 0.19.
E
Sell
5/1/2019Upgraded
XORTX Therapeutics Inc. (XRTXF) was upgraded to E+ from E on 5/1/2019 due to a noticeable increase in the total return index, volatility index and growth index. EBIT increased 57.18% from -$210.2 to -$90, earnings per share increased from -$0.0037 to -$0.0018, and operating cash flow increased 38.15% from -$152.3 to -$94.2.
XORTX Therapeutics Inc. (XRTXF) was upgraded to E+ from E on 5/1/2019 due to a noticeable increase in the total return index, volatility index and growth index. EBIT increased 57.18% from -$210.2 to -$90, earnings per share increased from -$0.0037 to -$0.0018, and operating cash flow increased 38.15% from -$152.3 to -$94.2.
E
Sell
3/4/2019Upgraded
XORTX Therapeutics Inc. (XRTXF) was upgraded to E from E- on 3/4/2019 due to an increase in the volatility index and total return index.
XORTX Therapeutics Inc. (XRTXF) was upgraded to E from E- on 3/4/2019 due to an increase in the volatility index and total return index.
E
Sell
2/26/2019None
XORTX Therapeutics Inc. (XRTX) was downgraded to E- from U on 02/26/2019.
XORTX Therapeutics Inc. (XRTX) was downgraded to E- from U on 02/26/2019.
NASDAQ
03/11/2025 3:58PM Eastern
Quotes delayed
